Free Trial
NASDAQ:CRBP

Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis

$58.00
+4.97 (+9.37%)
(As of 04:31 PM ET)
Today's Range
$52.78
$59.32
50-Day Range
$41.38
$60.28
52-Week Range
$3.03
$61.18
Volume
206,838 shs
Average Volume
572,314 shs
Market Capitalization
$619.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$73.25

Corbus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
26.7% Upside
$73.25 Price Target
Short Interest
Bearish
7.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.64mentions of Corbus Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$2.53 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($5.11) to ($5.18) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.94 out of 5 stars

Medical Sector

196th out of 896 stocks

Pharmaceutical Preparations Industry

86th out of 425 stocks

CRBP stock logo

About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Stock Price History

CRBP Stock News Headlines

Biden Pushing To Replace The Dollar With a Digital Coin, Control Currency.
Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Gap Up to $50.97
Biden Pushing To Replace The Dollar With a Digital Coin, Control Currency.
Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.
CRBP Corbus Pharmaceuticals Holdings, Inc.
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
See More Headlines
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2024
Today
7/19/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CRBP
Employees
19
Year Founded
2009

Price Target and Rating

Average Stock Price Target
$73.25
High Stock Price Target
$85.00
Low Stock Price Target
$46.00
Potential Upside/Downside
+33.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-44,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$880,000.00
Book Value
($1.56) per share

Miscellaneous

Free Float
10,260,000
Market Cap
$587.52 million
Optionable
Optionable
Beta
2.59

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Key Executives

  • Dr. Yuval Cohen Ph.D. (Age 49)
    CEO & Director
    Comp: $907.78k
  • Mr. Sean F. Moran CPA (Age 66)
    M.B.A., Chief Financial Officer
    Comp: $609.28k
  • Ms. Lindsey Smith
    Head of Corporate Communications & Patient Advocacy
  • Ms. Christina Bertsch
    Head of Human Resources
  • Dr. Dominic Smethurst M.A. (Age 49)
    M.D., Chief Medical Officer

CRBP Stock Analysis - Frequently Asked Questions

How have CRBP shares performed this year?

Corbus Pharmaceuticals' stock was trading at $6.04 at the beginning of 2024. Since then, CRBP stock has increased by 857.1% and is now trading at $57.81.
View the best growth stocks for 2024 here
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.26.

Who are Corbus Pharmaceuticals' major shareholders?

Top institutional shareholders of Corbus Pharmaceuticals include Assenagon Asset Management S.A. (2.23%). Insiders that own company stock include Yuval Cohen, Sean F Moran and Craig Stuart Millian.
View institutional ownership trends
.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL) and Matinas BioPharma (MTNB).

This page (NASDAQ:CRBP) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners